Scientific Article
previous document  unige:29866  next document
add to browser collection
Title

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"
Authors
Nast, Alexander
Augustin, Matthias
Boehncke, Wolf-Henning
Klaus, Joachim
Mrowietz, Ulrich
Ockenfels, Hans-Michael
Philipp, Sandra
Reich, Kristian
show hidden authors show all authors [1 - 15]
Published in Journal der Deutschen Dermatologischen Gesellschaft. 2010, vol. 8, no. 1, p. 65-66
Abstract In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
Keywords Antibodies, Monoclonal/adverse effects/*therapeutic use — Dermatology/*standards — European Union — *Evidence-Based Medicine — Humans — *Practice Guidelines as Topic — Psoriasis/*drug therapy
Identifiers
PMID: 20096063
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://onlinelibrary.wiley.com/store/10.1111/j.1610-0387.2009.07312_supp.x/asset/j.1610-0387.2009.07312_supp.x.pdf?v=...
Citation
(ISO format) 		NAST, Alexander et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". In: Journal der Deutschen Dermatologischen Gesellschaft, 2010, vol. 8, n° 1, p. 65-66. doi: 10.1111/j.1610-0387.2009.07312_supp.x https://archive-ouverte.unige.ch/unige:29866

348 hits

0 download

Contact an author

Update request

Update

Deposited on : 2013-09-20

Export document
Format :
Citation style :